Avicanna Inc. Provides Consolidated Revenue Guidance for the Fourth Quarter, Full Year 2021 and Full Year 2022
The company projected total fiscal 2021 revenue of $3.3 million, representing a 133% growth from $1.5 million in 2020.
For the full year 2022, the company projected $9 million in consolidated revenue from global operations, which is expected to be led by the anticipated sales of approximately 300,000 units of proprietary cannabinoid-based products.